Liquidia Technologies Inc (LQDA) - Total Liabilities
Based on the latest financial reports, Liquidia Technologies Inc (LQDA) has total liabilities worth $326.80 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LQDA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Liquidia Technologies Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Liquidia Technologies Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Liquidia Technologies Inc's balance sheet.
Liquidia Technologies Inc Competitors by Total Liabilities
The table below lists competitors of Liquidia Technologies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Taiwan Business Bank
TW:2834
|
Taiwan | NT$2.41 Trillion |
|
Glacier Bancorp Inc
NYSE:GBCI
|
USA | $27.49 Billion |
|
Maxscend Microelectronics Co Ltd
SHE:300782
|
China | CN¥5.42 Billion |
|
The Swatch Group AG
F:UHRA
|
Germany | €1.72 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥19.18 Billion |
|
China Coal Energy Company Limited
F:CVV
|
Germany | €169.68 Billion |
|
Fortnox AB
ST:FNOX
|
Sweden | Skr1.04 Billion |
|
Landstar System Inc
NASDAQ:LSTR
|
USA | $905.80 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Liquidia Technologies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See LQDA equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Liquidia Technologies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Liquidia Technologies Inc (2016–2025)
The table below shows the annual total liabilities of Liquidia Technologies Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $283.19 Million | +85.04% |
| 2024-12-31 | $153.04 Million | +115.43% |
| 2023-12-31 | $71.04 Million | +83.20% |
| 2022-12-31 | $38.78 Million | +36.23% |
| 2021-12-31 | $28.46 Million | +0.06% |
| 2020-12-31 | $28.45 Million | -16.08% |
| 2019-12-31 | $33.89 Million | +10.30% |
| 2018-12-31 | $30.73 Million | -36.68% |
| 2017-12-31 | $48.54 Million | +81.57% |
| 2016-12-31 | $26.73 Million | -- |
About Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung diseas… Read more